Clinically Optimal Versus “Target” Doses in Heart Failure
نویسندگان
چکیده
منابع مشابه
Higher medication doses in heart failure?
Bottom line In HF, higher-dose angiotensin-converting enzyme inhibitors (ACEIs), b-blockers (BBs), and angiotensin receptor blockers (ARBs) result in non-significant improvements in mortality, inconsistent decreases in HF hospitalizations, and more dizziness or hypotension (4% to 15%), dose reductions (20%), and stopping medication (2% to 8%). Starting patients on low doses and focusing on tole...
متن کاملHeart failure in a district general hospital: are target doses of beta-blockers realistic?
BACKGROUND Carvedilol therapy reduces mortality in patients with chronic heart failure. Multi-centre studies suggest a low first dose failure rate and high levels of tolerability to carvedilol. Little is known, however, concerning the eligibility and tolerance to treatment with carvedilol within a district general hospital setting. AIM To evaluate the eligibility and tolerance of patients wit...
متن کاملSilent disease progression in clinically stable heart failure
Heart failure with reduced ejection fraction (HFrEF) is a progressive disorder whereby cardiac structure and function continue to deteriorate, often despite the absence of clinically apparent signs and symptoms of a worsening disease state. This silent yet progressive nature of HFrEF can contribute to the increased risk of death-even in patients who are 'clinically stable', or who are asymptoma...
متن کاملIn‐hospital worsening heart failure: a clinically relevant endpoint?
Outcome measures used for the clinical evaluation of patients with acute heart failure differ between studies and may neither adequately address the characteristic presenting symptoms and signs nor reflect the pathophysiological processes involved. In-hospital worsening of heart failure (WHF) is associated with poor outcomes and thus a potential endpoint conveying clinically meaningful prognost...
متن کاملAdvances in Heart Failure Sodium Retention in Heart Failure and Cirrhosis Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist?
Patients with cirrhosis and heart failure (HF) share the pathophysiology of decreased effective arterial blood volume because of splanchnic vasodilatation in cirrhosis and decreased cardiac output in HF, with resultant stimulation of the renin-angiotensin-aldosterone system. Hyperaldosteronism plays a major role in the pathogenesis of ascites and contributes to resistance to loop diuretics. The...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2019
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2019.06.062